Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of Pittsburgh
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
Washington University School of Medicine
Delfi Diagnostics Inc.
Genentech, Inc.
Arbeitsgemeinschaft medikamentoese Tumortherapie
Taproot Health
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cedars-Sinai Medical Center
Sanguine Biosciences
Celldex Therapeutics
University of Nebraska
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eastern Cooperative Oncology Group
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute
Nantes University Hospital
Pfizer
National Institutes of Health Clinical Center (CC)
University of Dundee
Novartis
Fate Therapeutics
Celgene
National Institutes of Health Clinical Center (CC)
N.N. Petrov National Medical Research Center of Oncology
National Institutes of Health Clinical Center (CC)
Stanford University
Comprehensive Cancer Centers of Nevada
Ohio State University Comprehensive Cancer Center
Santa Maria Biotherapeutics
Memorial Sloan Kettering Cancer Center
Virginia Commonwealth University
The Cleveland Clinic
National Cancer Institute (NCI)
Northwestern University
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Indiana University
University of Chicago
University of Chicago
Altor BioScience
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)